These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 11142692)

  • 1. Anti-neoplastic activity of topotecan versus cisplatin, etoposide and paclitaxel in four squamous cell cancer cell lines of the female genital tract using an ATP-Tumor Chemosensitivity Assay.
    Boabang P; Kurbacher CM; Kohlhagen H; Waida A; Amo-Takyi BK
    Anticancer Drugs; 2000 Nov; 11(10):843-8. PubMed ID: 11142692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytotoxic effects of topotecan combined with various active G2/M-phase anticancer drugs in human tumor-derived cell lines.
    Taron M; Plasencia C; Abad A; Martin C; Guillot M
    Invest New Drugs; 2000 May; 18(2):139-47. PubMed ID: 10857993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines.
    Kaufmann SH; Peereboom D; Buckwalter CA; Svingen PA; Grochow LB; Donehower RC; Rowinsky EK
    J Natl Cancer Inst; 1996 Jun; 88(11):734-41. PubMed ID: 8637027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Supra-additive effect with concurrent paclitaxel and cisplatin in vulvar squamous cell carcinoma in vitro.
    Raitanen M; Rantanen V; Kulmala J; Helenius H; Grénman R; Grénman S
    Int J Cancer; 2002 Jul; 100(2):238-43. PubMed ID: 12115575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic cytotoxicity of topoisomerase I inhibitors with alkylating agents and etoposide in human brain tumor cell lines.
    Janss AJ; Cnaan A; Zhao H; Shpilsky A; Levow C; Sutton L; Phillips PC
    Anticancer Drugs; 1998 Aug; 9(7):641-52. PubMed ID: 9773809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro.
    Ma J; Maliepaard M; Nooter K; Boersma AW; Verweij J; Stoter G; Schellens JH
    Cancer Chemother Pharmacol; 1998; 41(4):307-16. PubMed ID: 9488600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study.
    O'Reilly S; Fleming GF; Barker SD; Walczak JR; Bookman MA; McGuire WP; Schilder RJ; Alvarez RD; Armstrong DK; Horowitz IR; Ozols RF; Rowinsky EK
    J Clin Oncol; 1997 Jan; 15(1):177-86. PubMed ID: 8996140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitivity to topoisomerase I inhibitors and cisplatin is associated with epidermal growth factor receptor expression in human cervical squamous carcinoma ME180 sublines.
    Ling YH; Donato NJ; Perez-Soler R
    Cancer Chemother Pharmacol; 2001 Jun; 47(6):473-80. PubMed ID: 11459199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design.
    Chou TC; Motzer RJ; Tong Y; Bosl GJ
    J Natl Cancer Inst; 1994 Oct; 86(20):1517-24. PubMed ID: 7932806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Predictive value of in vitro MTT assay chemosensitivity test of cytotoxic drug activity in cervical cancer].
    Xiao Y; Li JD; Shi HL; Liu JH; Feng YL; Li MD
    Ai Zheng; 2007 Apr; 26(4):386-9. PubMed ID: 17430657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein.
    Yang CH; Huang CJ; Yang CS; Chu YC; Cheng AL; Whang-Peng J; Yang PC
    Cancer Res; 2005 Aug; 65(15):6943-9. PubMed ID: 16061679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study.
    Long HJ; Bundy BN; Grendys EC; Benda JA; McMeekin DS; Sorosky J; Miller DS; Eaton LA; Fiorica JV;
    J Clin Oncol; 2005 Jul; 23(21):4626-33. PubMed ID: 15911865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination treatment with trabectedin and irinotecan or topotecan has synergistic effects against ovarian clear cell carcinoma cells.
    Kawano M; Mabuchi S; Kishimoto T; Hisamatsu T; Matsumoto Y; Sasano T; Takahashi R; Sawada K; Takahashi K; Takahashi T; Hamasaki T; Kimura T
    Int J Gynecol Cancer; 2014 Jun; 24(5):829-37. PubMed ID: 24844217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased cytotoxicity of squamous cell carcinoma of the head and neck by combining cisplatin with VP-16 and ciprofloxacin.
    Haller J; Burgess R; Dawson D
    Laryngoscope; 1993 Oct; 103(10):1081-3. PubMed ID: 8412441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoresistance testing of human ovarian cancer cells and its in vitro model.
    Brigulová K; Cervinka M; Tošner J; Sedláková I
    Toxicol In Vitro; 2010 Dec; 24(8):2108-15. PubMed ID: 20736059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix.
    Fiorica J; Holloway R; Ndubisi B; Orr J; Grendys E; Boothby R; DeCesare S; LaPolla J; Hoffman M; Patel J
    Gynecol Oncol; 2002 Apr; 85(1):89-94. PubMed ID: 11925125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.
    Hammond LA; Eckardt JR; Ganapathi R; Burris HA; Rodriguez GA; Eckhardt SG; Rothenberg ML; Weiss GR; Kuhn JG; Hodges S; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 1998 Jun; 4(6):1459-67. PubMed ID: 9626463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topotecan in cervical cancer.
    Ackermann S; Beckmann MW; Thiel F; Bogenrieder T
    Int J Gynecol Cancer; 2007; 17(6):1215-23. PubMed ID: 17997795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topotecan synergizes with CHEK1 (CHK1) inhibitor to induce apoptosis in ovarian cancer cells.
    Kim MK; James J; Annunziata CM
    BMC Cancer; 2015 Mar; 15():196. PubMed ID: 25884494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.